The results of two studies of long-term liver disease indicate Bristol-Myers Squibb's entecavir is more effective in treating hepatitis B than GlaxoSmithKline's Epivir. The studies in the New England Journal of Medicine, funded by Bristol-Myers, also said entecavir has a low rate of antiviral resistance.

Full Story:

Related Summaries